

Addiction Research

Nalmefene HCl

Opioid antagonist with a slower onset and longer duration of action than naloxone.¹ Also used as a treatment for alcohol dependence.²

Product No: 10-1049 100 mg/ 500 mg/

Bupropion HCl

Inhibitor of monoamine transporters DAT, NET, and SERT.³ Commonly used as a treatment for nicotine use disorder.⁴

Product No: 10-2462 50 mg/ 250 mg/

JNJ-63533054

Potent and selective brain-penetrant GPR139 agonist that decreased compulsive-like alcohol drinking in alcohol dependent rodents⁵ and suppressed morphine intake in a mouse self-administration model⁶.

Product No: 10-3880 5 mg/ 25 mg/

MPEP HCl

Potent metabotropic glutamate receptor antagonist that is selective for mGlu5. Reduced cocaine, ethanol, and nicotine self-administration in various models.⁷

Product No: 10-4007 5 mg/ 25 mg/

RGFP966

Selective HDAC3 inhibitor that facilitates the extinction of cocaine-seeking behavior in mice.⁸

Product No: 10-4029 5 mg/ 25 mg/

BD1063 dihydrochloride

Sigma-1 antagonist that has been used in animal models to successfully treat compulsive eating⁹ and excessive ethanol drinking¹⁰.

Product No: 10-4211 5 mg/ 25 mg/

SA4503

Potent and selective sigma-1 agonist that has been investigated as an anti-addiction agent.¹¹

Product No: 10-4219 5 mg/ 25 mg/

BD1047 dihydrobromide

Sigma-1 antagonist that attenuates cocaine's rewarding properties.¹² It also blocked the development, expression, and reinstatement of ethanol-induced conditioned place preference.¹³

Product No: 10-4210 5 mg/ 25 mg/

SBI-553


β -Arrestin-biased allosteric modulator of neurotensin receptor 1 (NTSR1). Attenuates cocaine and methamphetamine-induced hyperlocomotion and reduces cocaine self-administration in mice.¹⁴

Product No: 10-4449 5 mg/ 25 mg/


Varenicline tartrate

Selective partial agonist at the α 4 β 2 nicotinic receptor and full agonist at α 7 neuronal nicotinic receptors. It reduces nicotine-induced dopamine release and decreases nicotine self-administration. Clinically useful smoking-cessation agent.¹⁵

Product No: 10-2362 5 mg/ 25 mg/



Nalmefene HCl



SBI-553

REFERENCES

1. Osborn *et al.* (2010) *Life Sci.* **86** 624
2. Soyka and Rosner (2008) *Curr. Drug Abuse Rev.* **1** 280
3. Urra *et al.* (2014) *PLoS One* **9** e112834
4. Swinford-Jackson *et al.* (2021) *Cold Spring Harb. Perspect. Med.* **11** a040311
5. Kononoff *et al.* (2018) *eNeuro* **5** ENEURO.0153-18.2018
6. Wang *et al.* (2019) *Science* **365** 1267
7. Mihov and Hasler (2016) *Int. J. Neuropsychopharmacol.* **19** pyw002
8. Malvaez *et al.* (2013) *PNAS* **110** 2647
9. Cottone *et al.* (2012) *Neuropsychopharmacology* **37** 2593
10. Sabino *et al.* (2009) *Neuropsychopharmacology* **34** 1482
11. Mori *et al.* (2014) *Addict. Biol.* **19** 362
12. Romieu *et al.* (2002) *Neuropsychopharmacology* **26** 444
13. Bhutada *et al.* (2012) *Behav. Pharmacol.* **23** 25
14. Slosky *et al.* (2018) *Cell* **181** 1364
15. Shang *et al.* (2023) *J. Addict. Med.* **17** 536